Loading
The health technology assessment unit of Malaysia's Ministry of Health. It assesses new medicines, devices and procedures, writes the national clinical practice guidelines and scans for emerging technologies.
MaHTAS sits in the Medical Development Division of the Ministry of Health and describes itself as the ministry's custodian of evidence- and value-based medicine. It produces health technology assessment reports on drugs, biologics, devices, equipment, procedures and programmes, assessing effectiveness, safety, cost-effectiveness and organisational, social and ethical issues; it coordinates the development of clinical practice guidelines; and it runs horizon scanning for emerging technologies.
The National Strategic Plan for Cancer Control Programme 2021-2025 reports that the ministry's HTA unit assessed low-dose CT for lung cancer screening in 2017 and, because the test had high sensitivity but low specificity in high-risk people, recommended it only in a research setting; Malaysia has no national lung screening programme. The plan also describes value-based medicine as the ministry's route to deciding whether a new therapy is used in its hospitals.
OnCo found no published cost-effectiveness threshold for Malaysia. The coordinates are a Putrajaya centroid; the section's address was not read.
Shares National Pharmaceutical Regulatory Agency (NPRA), Malaysia, Institut Kanser Negara (National Cancer Institute, Malaysia), Ministry of Health Malaysia.
Shares Health technology assessment (HTA), reimbursement and QALYs, Lung cancer (all types).
Shares Ministry of Health Malaysia, Lung cancer (all types).
Shares Ministry of Health Malaysia, Lung cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/